1. Global asthma report.
http://globalasthmareport.org/
. Accessed 16 Oct 2018.
2. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–73.
3. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy. 2012;42:650–8.
4. Mepolizumab (NUCALA) US prescribing information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125526Orig1s000Lbl.pdf
. Accessed 4 Dec 2018.
5. Mepolizumab (NUCALA) EU summary of product characteristics.
https://www.ema.europa.eu/documents/product-information/nucala-epar-product-information_en.pdf
. Accessed 4 Dec 2018.